Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING

Subclass of:

435 - Chemistry: molecular biology and microbiology

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435239000 Recovery or purification 71
435236000 Inactivation or attenuation; producing viral subunits 37
Entries
DocumentTitleDate
20130040369Gammaretrovirus Associated With Cancer - The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.02-14-2013
20090047726Novel Clostridium perfringens Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of 02-19-2009
20100047896Nucleic acid construct containing full length genome of human hepatitis C virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus particle - The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.02-25-2010
20100075398Bacteriophage Preparations and Method of Use Thereof - Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of 03-25-2010
20100105122Oncolytic Viruses as Phenotyping Agents for Neoplasms - The present invention provides a method of diagnosing neoplasms having a particular phenotype by using oncolytic viruses that selectively replicate in neoplasms having the particular phenotype. For example, reovirus does not replicate in normal cells. However, reovirus selectively replicate in cells with an activated ras pathway, which leads to death of these cells. Therefore, a cell which becomes neoplastic due to, at least in part, elevated ras pathway activities can be diagnosed by its susceptibility to reovirus replication. This invention can further be applied, using other oncolytic viruses, to the diagnosis and/or treatment of other tumors, such as interferon-sensitive tumors, p53-deficient tumors and Rb-deficient tumors. Kits useful in the diagnosis or treatment disclosed herein are also provided.04-29-2010
20090186396ENHANCED PURIFICATION OF PHOSPHORYLATED AND NONPHOSPHORYLATED BIOMOLECULES BY APATITE CHROMATOGRAPHY - Methods are disclosed for the use of apatite chromatography, particularly without reliance upon phosphate gradients, for fractionation or separation of phosphorylated and nonphosphorylated biomolecules. Integration of such methods into multi-step procedures, with other fractionation methods are additionally disclosed.07-23-2009
20100323428ATTENUATED MINUS-STRANDED RNA VIRUS - An objective of the present invention is to provide attenuated minus-strand RNA viruses. The present inventors discovered that the amino acid mutation at position 1214 (Y1214F) in the amino acid sequence of L protein of Sendai virus suppressed the viral genome replication activity and/or transcription activity. The inventors also found that the deletion of a particular gene from the viral genome could result in much less cytotoxicity and immune response than conventional. The inventors thus completed the present invention.12-23-2010
20090155884AVIAN LEUKOSIS VIRUSES AND POLYPEPTIDE DISPLAY - The invention provides methods and materials involved in displaying polypeptide sequences using viruses such as avian leukosis viruses. Specifically, the invention provides nucleic acid molecules, collections of nucleic acid molecules, polypeptides, collections of polypeptides, viruses, and collections of viruses as well as methods for making nucleic acid molecules, collections of nucleic acid molecules, polypeptides, collections of polypeptides, viruses, and collections of viruses. The invention also provides methods for obtaining displayed polypeptide sequences that interact with biological molecules and/or cells as well as methods for identifying biological molecules that interact with displayed polypeptides.06-18-2009
20090155883Scientifically Modulated And Reprogrammed Treatment (SMART) Virus Technology Intended to Neutralize the Human Immunodeficiency Virus - The concept is to combat one of the deadliest infectious diseases known by fighting fire with fire. Scientifically Modulated And Reprogrammed Treatment (SMART) Virus technology is intended to neutralize the Human Immunodeficiency Virus. The SMART Virus carrying combinations of CD4, CCR5 and CXCR4 cell-surface receptors is capable of engaging the HIV's gp 120 and gp 41 exterior probes in an identical manner as would HIV's host, a T-Helper cell. When HIV encounters a SMART Virus the HIV virion would either adhere to the SMART Virus unable to further migrate in search of a T-Helper cell, harmlessly eject its RNA genetic payload or inject its RNA genome into the SMART Virus. Given HIV engaged a SMART Virus rather than a T-Helper cell, the HIV RNA genome becomes unable to infect a T-Helper cell, therefore the threat of Acquired Immunodeficiency Syndrome caused by HIV is averted.06-18-2009
20130052717MDCK CELL LINES SUPPORTING VIRAL GROWTH TO HIGH TITERS AND BIOREACTOR PROCESS USING THE SAME - The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.02-28-2013
20130052716JFH-1 BASED HCV CELL CULTURE SYSTEMS FOR NS5A OF GENOTYPES 1-7 - The present inventors developed hepatitis C virus recombinants expressing NS5A from genotype 1a, 1b, 2a, 3a, 4a, 5a, 6a or 7a in the context of a genotype 2a backbone. Additional recombinants express NS5A and the structural proteins (Core, E1 and E2), p7 and NS2 from genotype 1a, 1b, 3a, 4a, 5a, 6a or 7a in the genotype 2a backbone. Sequence analysis of the recombinants recovered after viral passage in Huh7.5 cells revealed adaptive mutations in NS5A and/or NS3. The importance of these mutations for improved growth kinetics was shown in reverse genetic studies.02-28-2013
20130089912METHODS AND COMPOSITIONS FOR THE STABILIZATION OF BIOLOGIC MATERIAL - A method of screening an organic salt for potential toxicity if used as a stabilizing agent for live cells or viruses, the method comprising: (a) providing a composition of unilamellar vesicles; then (b) contacting an organic salt to the unilamellar vesicles; and then (c) detecting a change in at least one thermal parameter of the unilamellar vesicles caused by the organic salt at said known concentration. A change in the at least one thermal parameter indicates the organic salt is potentially toxic for use as a stabilizing agent for live cells or viruses. Compositions of organic salts identified by such methods, along with methods of using the same in stabilizing live cells or viruses, are also described.04-11-2013
20090305385Novel Cultured Silkworm Cells Capable of Highly Efficient Baculovirus Production and Protein Production - Known cell lines derived from silkworm exhibit low propagation efficiency of BmNPV. Accordingly, systems using known culture cell lines derived from silkworms take a long time to establish recombinant viruses, and are not suitable for preparation of virus solutions with high titers. The present invention provides a cell line Bme21 (FERM P-20852) that is derived from a silkworm embryo and is highly susceptible to BmNPV or its variant having the same biological characteristics. The present invention also provides a method of producing a recombinant virus, a method of producing a recombinant protein, a method of increasing efficiency of recombinant virus production, and a method of increasing efficiency of recombinant protein production, using the cell line Bme21 or its variant.12-10-2009
20090093041METHODS FOR DRYING BACTERIOPHAGE AND BACTERIOPHAGE CONTAINING COMPOSITIONS, THE RESULTING DRY COMPOSITIONS, AND METHODS OF USE - Liquid bacteriophage products may be dried to form dry bacteriophage products. Drying may be effected by pulse combustion drying processes. When dried, the number of viable bacteriophage particles is reduced by no more than about two log (1004-09-2009
20130059362BIOSENSORS COMPRISING PROTEIN-BINDING DOMAINS AND FLUORESCENT PROTEINS - The present invention provides compositions and methods for monitoring cellular signal transduction events. In particular, signal transduction events may be monitored by the use of biosensors comprising protein-binding domains, which bind signal-transduction proteins, and fluorescent proteins. Provided herein, therefore, methods for detecting activation of signal transduction proteins or screening for agents that modulate the activity of signal transduction proteins. Also provided are cells comprising the biosensors; lentiviral particles comprising biosensor coding sequence; and kits comprising the lentiviral particles.03-07-2013
20110014682CARBON NANOTUBE BINDING PEPTIDES - Peptides have been generated that have binding affinity to carbon nanostructures and particularly carbon nanotubes. Peptides of or the invention are generally about twelve amino acids in length. Methods for generating carbon nanotube binding peptides are also disclosed.01-20-2011
20130065296BACULOVIRUSES WITH ENHANCED VIRION PRODUCTION AND A METHOD FOR THE PRODUCTION OF BACULOVIRUSES - A method of co-expressing a portion of the VSV G protein gene or a truncated “stem” portion with GP64 and a retrovirus increases the titer of retroviral vectors. A truncated VSV G protein, preferably comprised of a small segment from the C-terminal portion of the ectodomain plus the transmembrane (TM) and cytoplasmic tail (CTD) domains of VSV G, co-expressed with retroviral vectors, enhances the production titers of the retroviral vectors. A preferred embodiment uses a VSV G construct that includes an N-terminal c-Myc epitope plus 42 amino acids from the C-terminal portion of the ectodomain, 20 amino acids from the predicted TM domain, and 29 amino acids from the predicted CTD of the VSV G protein.03-14-2013
20110020907VIRUSES LACKING EPITHELIAL CELL RECEPTOR ENTRY - The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients. Specifically, the document provides nucleic acid molecules encoding viral hemagglutinin (H) polypeptides, viral H polypeptides, and viruses containing nucleic acids and/or H polypeptides. Such viruses are useful for vaccinations and for treating cancer patients as the viruses are not shed.01-27-2011
20110020906CARBON NANOTUBE BINDING PEPTIDES - Peptides have been generated that have binding affinity to carbon nanostructures and particularly carbon nanotubes. Peptides of or the invention are generally about twelve amino acids in length. Methods for generating carbon nanotube binding peptides are also disclosed.01-27-2011
20110020902CARBON NANOTUBE BINDING PEPTIDES - Peptides have been generated that have binding affinity to carbon nanostructures and particularly carbon nanotubes. Peptides of or the invention are generally about twelve amino acids in length. Methods for generating carbon nanotube binding peptides are also disclosed.01-27-2011
20110020901Methods of Making Viral Particles Having a Modified Cell Binding Activity and Uses Thereof - The present invention relates to a method for packaging viral particles such that one or more peptides on the surface of the virus particle are derived from the packaging cell. By incorporating certain peptides it is possible to target viral particles to specific cell types. Such a system is of use, for example, in gene therapy treatments.01-27-2011
20090239285TANDEM REAPEAT DNA CONSTRUCTS PRODUCING PROTEINS THAT ATTACK PLANT PATHOGENIC VIRUSES, FUNGI, AND BACTERIA BY DISRUPTING TRANSCRIPTION FACTORS ESSENTIAL FOR REPLICATION THEREOF IN PLANTS - Methods and compositions reduce growth of Geminiviruses employing a compound with the following structure:09-24-2009
20080318298Uncoupling of DNA insert propagation and expression of protein for phage display - The present invention provides an advance in phage display technology by permitting the uncoupling of the propagation of phages containing inserted sequences encoding heterologous polypeptides from the expression of said polypeptides. The invention provides phage constructs and methods for their use to permit phage coat protein expression, and thus phage propagation, in the absence of display of heterologous polypeptides, which may be expressed as a fusion with said coat protein in a regulated manner.12-25-2008
20120238000IMMORTALIZED AVIAN CELL LINES - This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.09-20-2012
20120237999HERPES SIMPLEX VIRUSES AND METHODS OF VIRAL REPLICATION - A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.09-20-2012
20080274533T4 BACTERIOPHAGE BOUND TO A SUBSTRATE - T4 bacteriophages are bound to substrates such as liposomes using a binder.11-06-2008
20100167377Recombinant viruses comprising the membrane-proximal domain of VSV G protein - Recombinant viruses, isolated nucleic acids and methods of generating same encoding for a Rhabdoviral G stem polypeptide are disclosed. Methods, compounds and compositions for target cell fusion potentiation mediated by Rhabdoviral G stem polypeptides, and applications of same are provided.07-01-2010
20090035836MODULATING PH-SENSITIVE BINDING USING NON-NATURAL AMINO ACIDS - The invention provides methods, systems and reagents for regulating pH-sensitive protein interaction by incorporating non-natural amino acids into the protein (e.g. an antibody, or its functional fragment, derivative, etc.). The invention also relates to specific uses in regulating pH-sensitive binding of antibodies to tumor site, by conferring enhanced tumor-specificity/selectivity. In that embodiment, the non-natural amino acids preferably have desirable side-chain pKa's, such that at below physiological pH (e.g. about pH 6.3-6.5) the non-natural amino acid confer enhanced binding to tumor antigens in acidic environments. Such non-natural amino acids can be incorporated by any suitable means, such as by utilizing a modified aminoacyl-tRNA synthetase to charge the nonstandard amino acid to a modified tRNA, which forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with natural tRNAs (e.g. the degenerate codon orthogonal system.02-05-2009
20110300605NANOSCALING ORDERING OF HYBRID MATERIALS USING GENETICALLY ENGINEERED MESOSCALE VIRUS - The present invention includes methods for producing nanocrystals of semiconductor material that have specific crystallographic features such as phase and alignment by using a self-assembling biological molecule that has been modified to possess an amino acid oligomer that is capable of specific binding to semi-conductor material. One form of the present invention is a method to construct ordered nanoparticles within the liquid crystal of the self-assembling biological molecule.12-08-2011
20110300604RECOMBINANT INFLUENZA VECTORS WITH TANDEM TRANSCRIPTION UNITS - The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.12-08-2011
20110287519HIGH YIELD YELLOW FEVER VIRUS STRAIN WITH INCREASED PROPAGATION IN CELLS - The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.11-24-2011
20090203112VERO CELL LINE WHICH IS ADAPTED TO GROW IN SUSPENSION - The invention relates to a Vero cell line that can be grown in serum-free and protein-free culture and in suspension culture in the absence of carrier for its adherence, and to production of viral vaccines using said cell line. More particularly, the present invention relates to establishment of a cell line that can be grown in suspension culture without need of the cells to be adhered to any supporting material. Furthermore, the present invention provides a process to obtain said Vero cell line and a process for producing viral vaccines with said cell line. The present invention further relates to the viruses obtained using the inventive method and to the vaccines formulated with said viruses.08-13-2009
20110294194EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 2B - The present inventors developed hepatitis C virus 2b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 2b reference strain J8. Sequence analysis of recovered 2b/2a recombinants from 2 transfection experiments revealed that 2b/2a was genetically stable. Conclusion: The developed 2b/2a viruses provide a robust in vitro tool for research in HCV genotype 2b, including vaccine studies and functional analyses.12-01-2011
20110294193VIRAL VECTORS AND METHODS FOR PRODUCING AND USING THE SAME - A recombinant hybrid virus, including: (a) a deleted adenovirus vector genome comprising the adenovirus 5′ and 3′ cis-elements for viral replication and encapsidation, and further comprising a deletion in an adenovirus genomic region selected from the group consisting of: (i) the polymerase region, wherein said deletion essentially prevents the expression of a functional polymerase protein from said deleted region and said hybrid virus does not otherwise express a functional polymerase protein, (ii) the preterminal protein region, wherein said deletion essentially prevents the expression of a functional preterminal protein from said deleted region, and said hybrid virus does not otherwise express a functional preterminal protein, and (iii) both the regions of (i) and (ii); and (b) a recombinant adeno-associated virus (AAV) vector genome flanked by the adenovirus vector genome sequences of (a), said recombinant AAV vector genome comprising (i) AAV 5′ and 3′ inverted terminal repeats, (ii) an AAV packaging sequence, and (iii) a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence is flanked by the 5′ and 3′ AAV inverted terminal repeats of (i). Methods of making and using the recombinant hybrid virus are also disclosed.12-01-2011
20090197320ANCESTRAL DENGUE VIRUS ENVELOPE PROTEIN - Disclosed is a dengue virus envelope protein sequence derived via ascertainment of a most recent common ancestor of the three dengue serotype variants, DENV-1, DENV-2, DENV-3 and DENV-4. This synthetic dengue virus envelope protein can be used as a tetravalent vaccine in the prevention of dengue fever, dengue hemorrhagic fever and dengue septic shock.08-06-2009
20100035327Use of rice-derived products in a universal cell culture medium - The invention is used as an additive to a culture medium to maintain and grow various cells including stem cells and support their manufactured and secreted products including cytokines, chemokines and growth factors in an environment which provides:02-11-2010
20090047727Novel Clostridium perfringens Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of 02-19-2009
20080311643Novel Pseudomonas aeruginosa: Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of 12-18-2008
20100112668Method For Producing Factor G Derived From HorseShoe Crab - The invention provides a virus harboring a DNA encoding a subunit of 05-06-2010
20100112667Microfluidic Biological Extraction Chip - A microfluidic cartridge for isolating biological molecules having a capture chamber containing functionalized solid supports maintained in a fluidized state provides reduced pressure drops and bubble formation during microfluidic extraction. The cartridge may include an electric field lysis chamber and/or a chemical lysis chamber. The electric-field lysis chamber may comprise an electrically insulating structure arranged between two opposing planar electrodes.05-06-2010
20100267117Bacteriophage Having Killing Activity Specific to Staphylococcus Aureus - The present invention relates to a novel bacteriophage, more precisely a novel bacteriophage having killing activity specific to 10-21-2010
20100267116Filovirus vectors and noninfectious filovirus-based particles - Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles.10-21-2010
20100120122TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.05-13-2010
20100120121Process for typing of HCV isolates - The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: 05-13-2010
20120034676SENECA VALLEY VIRUS BASED COMPOSITIONS AND METHODS FOR TREATING DISEASE - The present invention relates to a novel RNA 02-09-2012
20120107912CELL LYSIS DEVICE AND METHODS OF LYSING CELLS OR VIRUSES - A method of lysing at least one of a cell and a virus, the method including: contacting a sample, which includes at least one of a cell and a virus, with a plurality of beads which are disposed in a first chamber to obtain a combination of the sample and the beads; and agitating the combination of the sample and the beads to lyse the at least one of the cell and the virus, wherein in the first chamber a liquid volume fraction is 0.6 or less, and wherein the liquid volume fraction is a value obtained by dividing a liquid volume of the first chamber by a pure void volume equivalent to a sum of the liquid volume of the first chamber and a void volume of the first chamber.05-03-2012
20120107911RECOMBINANT HEMAGGLUTININ PROTEIN OF INFLUENZA VIRUS AND VACCINE CONTAINING THE SAME - The present invention provides a recombinant hemagglutinin antigenic protein, a virus-like particle and a recombinant influenza virus. The present invention further provides a vaccine comprising the recombinant hemagglutinin antigenic protein, the virus-like particle or recombinant influenza virus.05-03-2012
20120107910RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME - The present invention provides a recombinant HIV Env antigenic protein, a virus-like particle and a recombinant HIV virus. The present invention further provides a vaccine comprising the recombinant HIV Env antigenic protein, the virus-like particle or recombinant HIV virus.05-03-2012
20120107909NOVEL HIV-2 ISOLATE - The invention provides a novel strain of HIV-2 capable of causing immunodeficiency. The invention also provides compositions comprising the nucleic acids and polypeptides characteristic of this HIV-2 virus, antibodies specific for this HIV-2 virus, methods of using these compositions, and methods of detecting HIV-2 virus.05-03-2012
20090263883Recombinant Parainfluenza Virus Expression Systems And Vaccines Comprising Heterologous Antigens Derived From Respiratory Syncytial Virus - The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.10-22-2009
20110201087Compositions and Methods for the Production of Alpha-Herpesviruses - The present invention relates to virus growth media that improve the yield of alpha-herpesviruses (e.g., HSV-2) grown in cell cultures. The growth media of the invention include two additives, a disaccharide and a lipid mixture, that can be added to serum-free or serum-enriched growth media to improve the efficiency of virus production. The invention further provides methods of producing alpha-herpesviruses (e.g., HSV-2) in such growth media.08-18-2011
20090181446METHOD FOR PROPAGATING INFLUENZA VIRUS - A method for producing influenza virus on large scale is provided. A method for propagating influenza virus which comprises, after removing or decreasing a trypsin inhibitor secreted into culture of MDCK cells (cell line derived from dog kidney) by washing with a culture medium or a buffer, inoculating influenza virus into said cells and culturing said influenza virus-inoculated cells in a culture medium supplemented with trypsin.07-16-2009
20080206838Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus - The present invention includes methods for producing nanocrystals of semiconductor material that have specific crystallographic features such as phase and alignment by using a self-assembling biological molecule that has been modified to possess an amino acid oligomer that is capable of specific binding to semi-conductor material. One form of the present invention is a method to construct ordered nanoparticles within the liquid crystal of the self-assembling biological molecule.08-28-2008
20110171719Prevention and Remediation of Petroleum Reservoir Souring and Corrosion by Treatment with Virulent Bacteriophage - Petroleum reservoir souring, caused by microbially induced production of hydrogen sulfide and other sulfur compounds, and the attendant corrosion are remediated by isolating bacteriophage(s) specific for the problematic bacteria (target bacteria) and adding an effective amount of such bacteriophage(s) to water introduced into or resident in the reservoir to kill at least some of the target bacteria. Suitable virulent bacteriophage(s) may be indigenous to the water, located in surrounding areas, or taken from a known banked stock. Means of concentrating solutions of bacteriophage(s) are also disclosed.07-14-2011
20090104682Construction of novel strains containing minimizing genome by tn5-coupled cre/loxp excision system - Disclosed is a method for developing novel strains deleted specific chromosome sites, using transposon and Cre/loxP site-specific recombination by Cre expression vector, wherein the transposon comprises a selectable marker and loxP site. The method comprises the steps of: (1) preparing a transposon comprising a selectable marker and loxP site; (2) inserting the transposon into an optional position of microbial chromosome, and determining the inserted site; (3) integrating two transposons comprising a different selectable marker to one chromosome; (4) deleting a chromosomal site between the two lox sites by introducing a Cre expression vector into the chromosome of step (3); and (5) repeating steps (3 and 4) for the mutant deleted a part of chromosome, to shorten the chromosome of mutant gradually.04-23-2009
20110171720SINGLE-DOMAIN BRAIN-TARGETING ANTIBODY FRAGMENTS DERIVED FROM LLAMA ANTIBODIES - A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells (HCEC). From the enriched library, two sdAbs were selected, sequenced, subcloned, and expressed as fusion proteins with c-myc-His07-14-2011
20100279384ISOLATED REDUCTIVE DEHALOGENASE GENES - The invention is directed to novel reductive dehalogenase genes encoding for reductive dehalogenases which are capable of dehalogenating halogenated organic compounds and may be useful in the bioremediation of pollutants. In particular, the invention provides an isolated polynucleotide of a novel vinyl chloride dehalogenase gene (bvcA). The novel vinyl chloride dehalogenase gene encodes a reductive dehalogenase that is capable of the complete reduction of vinyl chloride to ethene.11-04-2010
20110201088Production of rAAV in Vero Cells Using Particular Adenovirus Helpers - The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).08-18-2011
20100136660METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS - A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods.06-03-2010
20120288916IMMORTALIZED AVIAN CELL LINES FOR VIRUS PRODUCTION - The present invention relates to immortalized avian cell lines suitable for production of biologicals or viruses for vaccination. In particular, the cell lines are derived from primary cells which are transformed with at least two viral or cellular genes, one of which causes cell cycle progression whereas the other interferes with innate protective mechanisms of the cell induced by dysregulated replication. The invention moreover relates to the production of said immortalized cell lines and their use for producing biologicals or viruses for vaccination.11-15-2012
20080241905Transgene Delivering Retrovirus Targeting Collagen Exposed At Site Of Tissue Injury - A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.10-02-2008
20110201086METHOD FOR PRODUCING RECOMBINANT VIRUS - To provide a method for producing, at high purity, a recombinant baculovirus which exhibits intended immunogenicity and is useful for a pharmaceutical (e.g., a vaccine), a transfer vector for use in the production of the recombinant baculovirus, and a method for producing the transfer vector. The method for producing a transfer vector which includes therein a fusion gene containing at least one gene encoding a virus-particle-forming protein and a gene encoding a foreign immunogenic protein, the method including modifying the polynucleotide sequence of the gene encoding the virus-particle-forming protein so as not to alter the amino acid residues constituting a corresponding naturally occurring virus-particle-forming protein and/or modifying the polynucleotide sequence of the gene so that a portion of the amino acid residues constituting the naturally occurring virus-particle-forming protein is deleted.08-18-2011
20080318299Isolated Human Cell, Method for Obtaining the Same and their Use - A novel cell suited for mass production of Hemagglutinating Virus of Japan (HVJ), a method for obtaining the cell and use of the cell are disclosed. The human cell is originated from a transformed human kidney cell line, the doubling time thereof in logarithmic growth phase in suspension culture in a serum-free medium is not more than 40 hours, the cell has a freeze-recovery property, the maximum density of viable cells in suspension culture is not less than 1012-25-2008
20100144014METHOD FOR AMPLIFYING HCV IN AEDES MOSQUITOES - A process for amplifying hepatitis C virus (HCV) in vivo is provided. The method includes ingesting06-10-2010
20090137023Cytoplasm of Eukaryotic cells for reprogramming of somatic cells, healing, repairing and therapeutic applications - The present invention relates to a method for cellular reprogramming, healing and repairing for therapeutic applications by removal of the cytoplasm from the cell, collecting the cytoplasm together to form a bath of cytoplasm and then immersing one or more somatic cells into the cytoplasm bath. Alternatively, the collection of cytoplasm can be injected or mixed in with a collection of somatic cells. This is dramatically different form all other approaches were transfer of cytoplasm and/or nucleus is performed by injection from one cell directly into another cell through varies methods. This method of immersing mammalian cells into a cytoplasm environment in particular a plutipotent stem cell cytoplasm environment has many potential uses.05-28-2009
20090004722Recombinant Parainfluenza Virus Expression Systems And Vaccines - The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.01-01-2009
20090004721Dengue virus mutant strain MBU 01-2002 - The invention includes a genetic construct and a mutant dengue virus, designated as strain MBU 01-2002, which is a mutant dengue virus generated by genetic modification of the 13-amino acid sequence just proximal to the pr-M junction within the prM coding region of the genome. The modification involves increasing the number of positively charged amino acid and abolishing the negatively charged amino acid in this pr-M junction sequence. The mutant dengue virus strain MBU 01-2002 possesses less prM protein on the viral envelope than the prototype dengue virus, is capable of inducing infected C6/36 cells to fuse at neutral pH, is as efficient as the prototype virus in the intracellular multiplication, but is defective in its release from infected cells.01-01-2009
20090203113CHIMERIC PAPILLOMAVIRUS-LIKE PARTICLES - The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines.08-13-2009
20090098632Compositions comprising viruses and methods for concentrating virus preparations - A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.04-16-2009
20090098633HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells - The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.04-16-2009
20090053790Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell - Proteins are provided for transferring a protein, an antibody or another foreign substance into a cell without impairing the function or structure thereof; and methods of transferring a foreign substance into a cell in a time and quantity controllable manner at a high efficiency by using the above-described delivery protein or an envelope virus or inactivated envelope virus in combination with said delivery protein. As the results of intensive studies on a method of enclosing a foreign substance in the envelope of an envelope virus, it is found out that a protein containing a polypeptide having an affinity for a constituent of the envelope virus contributes to the efficient enclosure of the foreign substance in the envelope. Moreover, it is found out that use of the aforementioned protein enables foreign substances to be included in an envelope virus or inactivated envelope virus and therefore the resulting foreign substance-containing envelope virus or inactivated envelope virus makes it possible to efficiently transfer the substances into cells without damaging the physiological function thereof.02-26-2009
20090053789PARTICLE BINDING - A method of binding bacteriophage to particles. The method comprising the steps of exposing the particles to an electrical discharge and then mixing the activated particles with the bacteriophage. The bacteriophage are then bound to the particles.02-26-2009
20090117643Tumor-targeting gene-virus zd55-il 24,its construction method and application thereof - This present invention disclosed a tumor-targeting gene-virus ZD55-IL-24, which is a recombinant Ad5 with a deletion of E1B 55K da gene and carries the anti-tumor gene IL-24. This present invention also disclosed its construction method and its application in cancer gene-therapy. The tumor-targeting gene-virus ZD55-IL-24 of this invention can be used in the therapy of many kinds of tumors, so it can be used in developing the new effective tumor therapy medicine.05-07-2009
20090197319Virus-Like Particle Containing A Dengue Recombinant Replicon - A diagnostic assay for detecting antibody, in part, to human papilloma virus includes a virus-like particle that expresses human papilloma virus antigen.08-06-2009
20080261289COMPOSITIONS COMPRISING VIRUSES AND METHODS FOR CONCENTRATING VIRUS PREPARATIONS - A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.10-23-2008
20090117644RECOMBINANT HSV USEFUL FOR TREATMENT OF HUMAN GLIOMA - The present invention provides a recombinant HSV having the ability to specifically kill tumor cells such as human glioma cells in vivo, useful and safe for treating human glioma, etc. and that can easily put to clinical use. A new recombinant HSV, KeM345, is constructed by inserting a γ34.5 gene transcription unit, which is expressed by Musashil promoter, into a ribonucleotide reductase gene site of the genome of a herpes simplex virus (HSV) previously attenuated, by means of homologous recombination and obtained as a purified strain. Since KeM345 is a recombinant virus itself, it can not only induce viral proliferation by being transmitted to culture cells but can also induce viral replication equivalent to that of wild-type HSV, showing an excellent cytotoxic effect (cytolytic ability) selectively upon a malignant glioma.05-07-2009
20100178684TRANSGENIC ONCOLYTIC VIRUSES AND USES THEREOF - The present disclosure relates to a recombinant oncolytic virus useful for inhibiting the growth of or killing tumor cells. More specifically, the recombinant oncolytic virus contains a heterologous nucleic acid sequence encoding an inflammation suppressive gene including, but not limited to, natural killer cell inhibitor, a chemokine binding protein, and an NF-κB inhibitor. Alternatively, the recombinant oncolytic virus contains a two or more heterologous nucleic acid sequences encoding one or more inflammation suppressive genes including, but not limited to, natural killer cell inhibitor(s), one or more chemokine binding protein(s), and/or one or more NF-κB inhibitor(s). Optionally, a recombinant oncolytic virus may further comprise one or more heterologous viral internal ribosome entry site (IRES) that is neuronally-silent. Such recombinant oncolytic viruses can be used to treat singular tumors or multi-focal tumors, such as those found in hepatocellular carcinoma or other cancers.07-15-2010
20090093040Bovine immunodeficiency virus (BIV) based vectors - This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.04-09-2009
20100184191NOVEL METHOD FOR GENERATION OF RNA VIRUS - The present invention provides a method for generating negative-strand, segmented RNA viruses using linear expression constructs in the presence of helper virus.07-22-2010
20090017522Polynucleotides Encoding Promyostatin Polypeptides - The present invention provides isolated polynucleotides encoding promyostatin polypeptides or a peptide portion thereof, polynucleotides complementary thereto, and oligonucleotides that can specifically hybridize to such polynucleotides. The present invention also provides an isolated polynucleotide encoding a mature myostatin peptide.01-15-2009
20110059513EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 1A AND 1B - The present inventors developed hepatitis C virus 1a/2a and 1b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a/2a and 1b/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis. The inventors in addition demonstrate the use of the developed systems for screening of antiviral substances in vitro and functional studies of the virus, e.g. identification of receptors required for HCV entry03-10-2011
20110059512EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 6A - The present inventors developed hepatitis C virus 6a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 6a reference strain HK6a. Sequence analysis of recovered 6a/2a recombinants from 2 transfection experiments and subsequent reverse genetic studies revealed adaptive mutations in E1 and E2. Conclusion: The developed 6a/2a viruses provide a robust in vitro tool for research in HCV genotype 6, including vaccine studies and functional analyses.03-10-2011
20130217095CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT - The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.08-22-2013
20100136659Infectious cDNA Clone of North American Porcine Reproductive and Respiratory Syndrome (PPRS) Virus and Uses Thereof - The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus. These viral vectors and transfected host cell lines are useful in providing peptides to compensate for mutated peptide coding sequences of DNA sequences encoding genetically-modified North American PRRS viruses so that functional virions can be generated.06-03-2010
20100151556HYBRID AND SINGLE CHAIN MEGANUCLEASES AND USE THEREOF - This patent application relates to hybrid and/or single-chain rare-cutting endonucleases, called meganucleases, which recognize and cleave a specific nucleotide sequence, to polynucleotide sequences encoding for said rare-cutting endonucleases, to a vector comprising one of said polynucleotide sequences, to a cell or animal comprising one of said polynucleotide sequences or said rare-cutting endonucleases, to a process for producing one of said rare-cutting endonucleases and any use of the disclosed products and methods. More particularly, this invention contemplates any use of such rare-cutting endonuclease for genetic engineering and gene therapy.06-17-2010
20120034677MICROORGANISM CULTURE DEVICE AND METHOD OF OPERATION THEREOF - The invention is directed to a microorganism culture device (02-09-2012
20100196992INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.08-05-2010
20100221811RECOMBINANT ADENOVIRUS USEFUL FOR TREATING MALIGNANCY OVER-EXPRESSING PROTO-ONCOGENE NEU/ERB B2 - A recombinant adenovirus is applied for treating malignancy of over-expressing proto-oncogene neu/erbB2, wherein an expression cassette, which co-expresses the humanized monoclonal antibody variable region gene of anti proto-oncogene neu/erbB2 and the Mda-7/IL-24 gene, is inserted into E1 deletion region of the recombinant adenovirus. The recombinant adenovirus effectively treats the malignancy of overexpressing proto-oncogene neu/erbB2 without damaging normal cells, such that the recombinant adenovirus is able to be used for the gene therapy of malignancy tumors over-expressing proto-oncogene neu/erbB2.09-02-2010
20110027861Desiccated Biologics And Methods Of Preparing The Same - The present invention provides compositions comprising desiccated biologics comprising a cell, protein, virus, nucleic acid, carbohydrate, or lipid, or any combination thereof, along with at least one membrane penetrable sugar, and at least one membrane impenetrable sugar, wherein the moisture content is from 5% to 95%, and to methods of preparing the same, and to methods of treating animals using the same.02-03-2011
20100297731Novel adenoviruses, nucleic acids that code for the same and the use of said viruses - The present invention is related to an adenovirus expressing a first protein which is selected from the group comprising an E1B protein and an E4 protein, prior to a second protein which is selected from the group comprising an E1A protein.11-25-2010
20100297730Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus - The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human 11-25-2010
20110111480Telomelysin/GFP-expressing recombinant virus - The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome.05-12-2011
20090047728ADENOVIRAL VECTORS FOR INFLUENZA VIRUS PRODUCTION - The invention provides adenovirus and retrovirus vectors useful to prepare influenza virus. Also provided is a canine RNA polymerase I promoter and vectors having that promoter.02-19-2009
20100297732VECTORS WITH MODIFIED PROTEASE-DEPENDENT TROPISM - The present invention provides cell fusogenic vectors having replicative ability, whose protease-dependent tropism has been modified. M gene-deficient viral vectors encoding modified F proteins, in which the cleavage site of the F protein of paramyxovirus is modified to be cleaved by different proteases, were produced. In cells transfected with these vectors, the genomic RNA present in the vectors is replicated, and cell fusogenic infection spreads to neighboring cells depending on the presence of other proteases; however, no viral particles are released. The vectors of this invention, encoding the F proteins which are cleaved by proteases whose activity is enhanced in cancer, show cancer growth suppressive effect in vivo.11-25-2010
20100255559APPARATUS AND PROCESS FOR TREATING AN AQUEOUS SOLUTION CONTAINING BIOLOGICAL CONTAMINANTS - Process, apparatus and article for treating an aqueous solution containing biological contaminants. The process includes contacting an aqueous solution containing a biological contaminant with an aggregate composition comprising an insoluble rare earth-containing compound to form a solution depleted of active biological contaminants. The aggregate includes more than 10.01% by weight of the insoluble rare earth-containing compound. The insoluble rare earth-containing compound can include one or more of cerium, lanthanum, or praseodymium. A suitable insoluble cerium-containing compound can be derived from a cerium carbonate, a cerium oxalate or a cerium salt. The composition can consist essentially of cerium oxides, and optionally, a binder and/or flow aid. The aggregate includes no more than two elements selected from the group consisting of yttrium, scandium, and europium when the aggregate is to be sintered. Although intended for a variety of fluid treatment applications, such applications specifically include removing or deactivating biological contaminants in water.10-07-2010
20110008871Production of Homogeneous Cell Line Highly Permissive To Porcine Circovirus Type 2 (PCV2) Infection - Continuous cell lines that are highly permissive to infection by porcine circovirus type 2 (“PCV2”) are described. PCV2 is the causal agent of post-weaning multi-systemic wasting syndrome (“PMWS”) in pigs. PMWS has emerged as a major disease that poses a significant threat to the economics of global swine industry. The highly permissive cell lines of this invention provide efficient and reliable sources of PCV2 for use in development of vaccines, therapies and diagnostic agents for PMWS.01-13-2011
20110008872Immortalized Avian Cell Lines - This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.01-13-2011
20090142823ATTENUATED RNA VIRUS AND APPLICATIONS THEREOF - The invention encompasses an attenuated RNA virus and methods of using an attenuated RNA virus. The RNA virus comprises, in part, an ion channel protein comprising a peptide tag.06-04-2009
20110117627REGULATION OF APOPTOSIS BY NEURAL SPECIFIC SPLICE VARIANTS OF IG20 - Pro-apoptotic signaling caused by down-modulation of KIAA0358 or expression of IG20-SV4 effectively induces spontaneous apoptosis and sensitization to TNFα-induced apoptosis in neuroblastoma cells. Methods and composition to enhance cell death in neuroblastoma are provided. Methods and compositions to reduce cell death in neurodegenerative disorders are provided.05-19-2011
20110244552Methods and compositions for the production of recombinant virus vectors - A method for the production of a replication-deficient recombinant virus vector is disclosed. The replication-deficient recombinant virus vector has a recombinant virus genome with one or more defective viral genes. The method comprises infecting a host cell with a carrier virus having a carrier virus genome encoding one or more trans factors or variants thereof, incubating the infected host cell for a desired period of time, and isolating the replication-deficient recombinant virus vector. The carrier virus is a cytoplasmic virus that retains the carrier virus genome in the cytoplasm of the host cell. The host cell contains the recombinant viral genome and retains the recombinant viral genome in a nucleus of the host cell. Also disclosed is a carrier virus for the production of a replication-deficient recombinant virus vector.10-06-2011
20110143423Viral vectors whose replication and, optionally, passenger gene are controlled by a gene switch activated by heat in the presence or absence of a small-molecule regulator - The present invention relates to conditionally replicating viruses or pairs of viruses containing a gene switch that is activatable by transient heat or other proteotoxic stress in the presence or absence of a small molecule regulator. The gene switch controls the expression of a gene for a protein required for efficient viral replication and may also control the activity of a passenger gene.06-16-2011
20110236956MULTICISTRONIC siRNA CONSTRUCTS TO INHIBIT TUMORS - Multicistronic short interfering RNA constructs targeting in various combinations a human urokinase-type plasminogen activator receptor (uPAR), human urokinase-type plasminogen activator (uPA), human matrix metalloprotease 9 (MMP-9) and cathepsin B (CB) inhibit tumors.09-29-2011
20110086415Electrospun Fiber Pre-Concentrator - The present disclosure relates, in some embodiments, to pre-concentrator compositions, devices, systems, and/or methods for concentrating small quantities of chemical or biological compounds, e.g., CBRNE compounds. A pre-concentrator of the disclosure may be operable to releasably bind and concentrate CBRNE compounds. In some embodiments, a pre-concentrator may comprise a 3-D structure of electrospun nanofibers, that comprise at least one polymer, one conducting agent and at least one chemical-specific functional group and/or biological-specific moiety configured to selectively bind to a CBRNE compound. Bound compounds may be released and detected. Pre-concentrator devices and systems operable to bind, concentrate, and/or detect one or more CBRNE compounds are described. Devices and systems of the disclosure may be configured to concentrate and detect multiple compounds. Methods for synthesizing pre-concentrators as well as methods for concentrating, detecting and identifying compounds of interest are also set forth.04-14-2011
20100173388RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRAL GENOME - The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.07-08-2010
20090215147Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy - The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity.08-27-2009
20090215146Method for Producing Virus-Type Particles Containing an Active Substance - The invention relates to a method for producing virus-type particles containing an active substance. Proteins, which comprise a first amino acid sequence which is derived from a first virus protein, and fusion proteins are assembled in order to form the virus-type particles. The proteins and the fusion proteins are coexpressed in yeast cells.08-27-2009
20100015687Tetracycline Repressor Regulated Oncolytic Viruses - The present invention is directed oncolytic Herpes simplex-1 viruses whose replication is controlled using a tetracycline operator/repressor system. The invention also includes DNA sequences used in making the viruses and methods in which these viruses are used in the treatment of cancer patients with solid tumors.01-21-2010
20110151542Bionanomaterials and Their Synthesis - The use of biomaterials, such as viruses and virus-like particles, to form nanostructures is generally disclosed. For instance, rod-like viruses can be used to form composite nanofibers that are fixed together in a head-to-tail assembly by a polymer. Also, 2-dimensional nanostructures formed from crosslinked viruses assembled in a single, film-like layer are generally disclosed. Porous gels having controllable pore size through the use of virus particles are also disclosed.06-23-2011
20100068787Novel Staphylococcus aureus: Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of 03-18-2010
20090215148Conjugates of biological substances - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and the 3-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivate compounds having one or more benzo nitrogens.08-27-2009
20110070623SELF-INACTIVATING HELPER ADENOVIRUSES FOR THE PRODUCTION OF HIGH-CAPACTIY RECOMBINANT ADENOVIRUSES - The invention relates to reagents and methods for the generation of auto-inactivating helper adenoviruses that allow the development of cell systems for the generation of high-capacity recombinant adenovirus showing a reduced contamination by auxiliary adenoviruses.03-24-2011
20090023196Stocks of replication-deficient adenovirus - Presented are ways to address the problem of replication-competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector are suited for large scale production of recombinant adenoviruses. A system for use with the invention produces replication-defective adenovirus. The system includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, has at least one functional encapsidation signal and at least one functional Inverted Terminal Repeat, and lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication-competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.01-22-2009
20110250675Virus-Like Particle Mediated Cellular Delivery - The invention provides compositions and methods for delivering compounds to cells. The invention is directed, in part, to virus-like particles which contain biological materials such as carbohydrates, proteins and nucleic acids. The invention is also directed, in part, to methods for delivering compounds to cells involving contacting cells with the compounds under conditions which allow for uptake of the compounds by cells and release of the compounds into the cells which take it up.10-13-2011
20090239286PRODUCTION OF POXVIRUSES WITH ADHERENT OR NON ADHERENT AVIAN CELL LINES - The present invention relates to a method for replicating poxviruses such as vaccinia virus comprising the steps of inoculating avian embryonic stem cells with viral particles and culturing said cells in a basal medium until cells lysis occurs and newly produced viral particles are released in said medium.09-24-2009
20090029441BIONANOMATERIALS AND THEIR SYNTHESIS - The use of biomaterials, such as viruses and virus-like particles, to form nanostructures is generally disclosed. For instance, rod-like viruses can be used to form composite nanofibers that are fixed together in a head-to-tail assembly by a polymer. Also, 2-dimensional nanostructures formed from crosslinked viruses assembled in a single, film-like layer are generally disclosed. Porous gels having controllable pore size through the use of virus particles are also disclosed.01-29-2009
20080268522LENTIVIRAL PACKAGING CONSTRUCTS - The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.10-30-2008
20110020904CARBON NANOTUBE BINDING PEPTIDES - Peptides have been generated that have binding affinity to carbon nanostructures and particularly carbon nanotubes. Peptides of or the invention are generally about twelve amino acids in length. Methods for generating carbon nanotube binding peptides are also disclosed.01-27-2011
20110020903CARBON NANOTUBE BINDING PEPTIDES - Peptides have been generated that have binding affinity to carbon nanostructures and particularly carbon nanotubes. Peptides of or the invention are generally about twelve amino acids in length. Methods for generating carbon nanotube binding peptides are also disclosed.01-27-2011
20110020905CARBON NANOTUBE BINDING PEPTIDES - Peptides have been generated that have binding affinity to carbon nanostructures and particularly carbon nanotubes. Peptides of or the invention are generally about twelve amino acids in length. Methods for generating carbon nanotube binding peptides are also disclosed.01-27-2011
20110053249Adenoviruses Mutated In The VA Genes For Cancer Treatment - This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs.03-03-2011
20110053248 Serum-Free Virus Propagation Platform For A Virus Vaccine Candidate - The invention relates to methods for propagating viruses. In particular, the invention provides optimized conditions for propagating viruses. Optimization of the following parameters are provided: lipid concentrates as supplements to the medium, temperature shift from pre-infection to post-infection, multiplicity of infection, direct bead-to-bead transfer and serum supplementation of pre-infection medium. In particular, the invention provides for the first time a method for propagating a virus by culturing cells that are infected with the virus in a medium comprising chemically defined lipid concentrate (CDLC). In another claim, the CDLC is added to medium that is substantially free of serum for culture of virus-infected cells.03-03-2011
20110027863LABORATORY VESSEL WITH SHIFTABLE VESSEL CLOSURE - The present invention pertains to vessels with a vessel closure, and in particular to laboratory vessels with a shiftable closure assembly. The laboratory vessel comprises a container comprising an outwardly extending neck with an opening which provides access to the interior of said container, at least one guiding device comprising a guided member and a guiding member, a closure assembly comprising a vessel closure and at least one guided member which is part of said at least one guiding device, which is characterized in that said vessel closure is arranged to be shifted away from said opening to provide access to the interior of the container, wherein said at least one guiding device guides the shifting of the closure assembly and retains it in connection with the container even in the position in which the vessel closure is removed from the opening.02-03-2011
20110027862SAMPLE STABILIZATION - This disclosure relates to reagents, compositions, methods for stabilising RNA in an RNA-containing sample by contacting the sample with guanidine and a metal ion to form a stabilised RNA-containing composition in which the metal ion is present at a concentration which is no more than 20 mM, and the metal ion is derived from a metal other than from a Group 1 or Group 2 metal.02-03-2011
20100285570FLUORIDE PROCESSING METHOD - The invention relates to methods for processing [11-11-2010
20110136209PROCESS FOR THE PREPARATION OF NICOTINE-BASED HAPTENS - A process for preparing a nicotine-based hapten of formula I06-09-2011
20110136208ANTIGEN-SPECIFIC REGULATORY T-CELL INDUCTION - The present invention relates to an infectious particle having a surface displaying a ligand binding to a CD4 receptor for selectively infecting dividing CD406-09-2011
20100184192AVIAN INFLUENZA CHIMERIC VLPS - This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs07-22-2010
20100144015COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH - Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.06-10-2010
20100184190Influencing viral lipid constituents - This invention provides compositions, methods and systems to modulate the lipid content and membrane characteristics of cells and virions. Growth of host cells on media containing particular amounts, classes and/or combinations of lipid supplements can influence the lipid content of the cell and viruses grown on the cell. Lipids, such as cholesterol esters, sphingomyelin, glycolipids, containing C16:0, C18:0, C18: 1n9 and/or C18:2n6 fatty acids, can influence cell permissivity for virus infection, virus yield, virus immunogenicity and/or membrane phase transition temperatures.07-22-2010
20090203114NOVEL METHODS AND INTERFERON DEFICIENT SUBSTRATES FOR THE PROPAGATION OF VIRUSES - The present invention relates, to novel methods and substrates for the propagation of viruses. The invention relates to IFN-deficient substrates and methods for propagating viruses in these unconventional substrates. In particular, the invention relates to methods of propagating viruses in immature embryonated eggs, preferably six- to nine-day-old chicken eggs. The methods of the invention are particularly attractive for growing viruses suitable for use in vaccine and pharmaceutical formulations.08-13-2009
20100190234 METHODS FOR THE FORMATION OF DISULPHIDE BONDS - The present invention relates to methods for the formation of inter-molecular disulphide bonds, including (poly)peptides/proteins, nucleic acids, vectors, host cells and bacteriophages used in these methods. Furthermore the invention relates to the use of this method for the improved display of (poly)peptides/proteins on the surface of bacteriophage particles.07-29-2010
20100190232Functional Mutations In Respiratory Syncytial Virus - The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided.07-29-2010
20110263001Compositions and Methods for Engineering Cells - The disclosure relates generally to genetic manipulation of stem and primary cells and to reprogramming of somatic cells, more specifically, human cells. In particular, compositions and methods are disclosed for the generation and maintenance of such engineered cells.10-27-2011
20100028973METHOD FOR PROLIFERATING HEPATITIS VIRUS, HOLLOW FIBER FOR CULTURING HEPATITIS VIRUS-INFECTED CELLS, AND USE THEREOF - The present invention provides (i) a method for proliferating a hepatitis virus, the method including the steps of: infecting, with the hepatitis virus, cells packed into a lumen of a hollow fiber made of a permeabilized membrane; and culturing the cells or (ii) a method for proliferating a hepatitis virus, the method including the steps of: infecting cells with the hepatitis virus; packing the cells into a lumen of a hollow fiber made of a permeabilized membrane; and culturing the cells. This provides an experimental system for infecting in vitro culture cells with a hepatitis virus such as HBV or HCV and then proliferating the hepatitis virus.02-04-2010
20110143422RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HYPIV2) FROM CDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS - Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.06-16-2011
20120040439Use of Prokaryote Viruses to Remediate Bio-Fouling - This invention provides a process for control in oil and gas wells and related facilities of prokaryote caused souring, fouling and corrosion by reduction of problematic prokaryotes with naturally occurring lysing organisms, particularly sulfate-reducing prokaryotes by proliferating suitable virulent lysing organisms under conditions in which problematic prokaryotes thrive, including in a gas production wellbore. The process provides in situ proliferation of virulent lysing organism in a wellbore by providing both virulent lysing organisms and their host prokaryotes to selectively grow an effective control amount and concentrations of lysing organisms in a well formation.02-16-2012
20120040438Novel Porcine Circovirus Type 2B Isolate and Uses Thereof - The present invention relates to the novel Porcine Circovirus type 2 subtype B (PCV2B-Rm) isolate which comprises a short duplication of sequence and is adapted to grow in cell culture and may be propagated at high titres constantly up to 1002-16-2012
20090239287Production of vaccines - Means and methods are provided for the production of mammalian viruses comprising: infecting a culture of immortalized human cells with the virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages are that human cells of the present invention can be cultured under defined serum free conditions, and the cells show improved capability for propagating virus. In particular, methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity to use whole chicken embryos for the production of influenza vaccines. The method provides also for the continuous or batchwise removal of culture media. As such, the invention allows the large-scale, continuous production of viruses to a high titer.09-24-2009
20100190233M13 Bacteriophage as A Chemoaddressable Nanoparticle for Biological and Medical Applications - Reactive and modified M13 bacteriophages, and methods of making and using the same, are generally provided. The reactive M13 bacteriophage can include a alkyne functional group covalently attached to the M13 bacteriophage. The modified M13 bacteriophage can include a substituent covalently attached to the M13 bacteriophage via a 1,2,3-triazole linkage. Dual-modified M13 bacteriophages are also generally provided, and can include a cancer-targeting substituent covalently attached to the M13 bacteriophage and a fluorescent group covalently attached to the M13 bacteriophage. The modified M13 bacteriophages can not only be employed as a fluorescent probe for cancer imaging, but also can be used as biomaterials for cell alignment and scaffolding.07-29-2010
20110318813CHIMERIC PESTIVIRUS WITH INSERTION IN 3' NONTRANSLATED REGION (3' NTR) WITH STABLE REPLICATION AND RNASE RESISTANCE - The construction of a chimeric Pestivirus by the identification of selected regions in the 3′NTR of the viral RNA genome is described where additional RNA sequences can be stably inserted. These sequence insertions in the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3′NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays.12-29-2011
20120045819BINDING MOLECULES FOR HUMAN FACTOR VIII AND FACTOR VIII-LIKE PROTEINS - It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.02-23-2012
20120003719INFECTIOUS GENOTYPE 1a, 1b, 2a, 2b, 3a, 5a, 6a and 7a HEPATITIS C VIRUS LACKING THE HYPERVARIABLE REGION 1 (HVR1) - The present inventors used the previously developed H77/JFH101-05-2012
20100136657METHOD FOR STORING SILICA-BASED MATERIAL, PACKAGE PRODUCED WITH THE METHOD AND USE OF PACKAGE FOR PACKAGING OF SILICA-BASED PRODUCTS - A method for storing a water-soluble undissolved silica-based material, optionally with an incorporated functional agent. The method includes immersing the material in an aqueous liquid phase which is initially saturated with a water-soluble silica-based material which is the same or different than the undissolved silica-based material, such that the undissolved silica-based material does not essentially dissolve into the liquid phase during storage, or the proportion of the amount of the initially undissolved silica-based material to the amount of the liquid phase is such that the liquid phase will be saturated or essentially saturated by a dissolved portion of the water-soluble undissolved silica-based material during storage, which dissolved portion of said water soluble undissolved silica-based material is less than 20%. Also disclosed is a storage package which may preferably be used to store functional agents, delivery devices or implants.06-03-2010
20120015423INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.01-19-2012
20120021491IDENTIFICATION OF ANTIGEN OR LIGAND-SPECIFIC BINDING PROTEINS - The present invention discloses novel methods for the generation, expression and screening of diverse collections of binding proteins such as antibodies or fragments thereof in vertebrate host cells in vitro, for the identification and isolation of ligand- or antigen-specific binding proteins. The methods disclosed herein allow the expression of diverse collections of binding proteins from at least one vector construct, which optionally can give rise to collections of diverse binding proteins upon transfer and expression into vertebrate host cells in situ.01-26-2012
20090075357PRODUCTION OF RECOMBINANT AAV VIRIONS - Stocks of infectious rAAV are generated using yeast strains, bacterial strains, and bacteriophages engineered to express the required AAV proteins and harboring rAAV vector sequences. Stocks of rAAV virions of all serotypes and pseudotypes can be generated in prokaryotic and eukaryotic cells using the methods described herein.03-19-2009
20120058538Helper-free Rescue of Recombinant Negative Strand RNA Virus Systems - The present invention relates methods of generating infectious negative-strand virus in host cells by an entirely vector-based system without the aid of a helper virus. In particular, the present invention relates methods of generating infectious recombinant negative-strand RNA viruses intracellularly in the absence of helper virus from expression vectors comprising cDNAs encoding the viral proteins necessary to form ribonucleoprotein complexes (RNPs) and expression vectors comprising cDNA for genomic viral RNA(s) (vRNAs) or the corresponding cRNA(s). The present invention also relates to methods of generating infectious recombinant negative-strand RNA viruses which have mutations in viral genes and/or which express, package and/or present peptides or polypeptides encoded by heterologous nucleic acid sequences. The present invention further relates the use of the recombinant negative-strand RNA viruses or chimeric negative-strand RNA viruses of the invention in vaccine formulations and pharmaceutical compositions.03-08-2012
20120064603SELECTIVE ACCESS TO CRYOPRESERVED SAMPLES - Methods and apparatus for selectively accessing a portion of a sterile cryopreserved sample are disclosed. The apparatus may include a container configured to receive the cryopreserved sample and having a first portion and a second portion, a heat sink chamber surrounding the first portion of the container, and a heat source adjacent to the second portion of the container. The chamber may be configured to maintain a non-accessed portion of the sample in a cryopreserved state. The heat source may be configured to separating an accessed portion of the sample from the non-accessed portion of the sample while maintaining the viability of the accessed portion while the non-accessed portion is maintained in the cryopreserved state.03-15-2012
20100136658GENERATION OF ONCOLYTIC ADENOVIRUSES AND USES THEREOF - The present invention relates to a method for the production of onolytic adenoviruses having increased potency and their therapeutic applications for cancer. Recombinant adenoviruses and methods to produce them are provided.06-03-2010
20110104789NON-INTEGRATING REV-DEPENDENT LENTIVIRAL VECTOR AND METHODS OF USING THE SAME - Non-integrating, Rev-dependent (NIRD) lentiviral vectors and NIRD lentiviral particles carrying a therapeutic gene, such as DT-A or TRAF6 and methods of making the same are disclosed. The intracellular expression of DT-A or TRAF6 results in the selective killing of HIV-positive cells and, thus, these NIRD lentiviral vectors and lentiviral particles can be used in methods to kill HIV-infected cells or treat to HIV-infected subjects. Also disclosed is a human cell line comprising a mutation in the EF2 gene that confers resistance to DT-A.05-05-2011
20110104788Modulation of Adenoviral Tropism - The invention provides materials and methods for modulating adenoviral tropism for hepatocytes and other cell types such as splenocytes. It relates to the findings that hypervariable regions (HVRs) of the viral hexon protein interact with the Gla domain of the blood clotting factor FX as part of the infective process in vivo. The invention provides means to disrupt the interaction between hexon and FX, thus reducing infection of hepatocytes and splenocytes, as well as use of targeting agents comprising the Gla domain or a fragment thereof to direct adenoviral vectors to desired target cell or tissue types.05-05-2011
20120122185Chimeric viruses presenting non-native surface proteins and uses thereof - The present invention provides chimeric negative-stand RNA viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein. Such chimeric viruses induce an immune response against influenza virus and the infectious agent. The present invention also provides chimeric Newcastle Disease viruses (NDV) engineered to express and incorporate into their virions a fusion protein comprising the ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an NDV protein. Such chimeric viruses induce an immune response against NDV and the infectious agent.05-17-2012
20120122186NOVEL BACTERIOPHAGE STRAINS FOR THE TREATMENT OF BACTERIAL INFECTIONS, ESPECIALLY DRUG RESISTANT STRAINS OF THE GENUS ENTEROCOCCUS - Novel bacteriophage strains are disclosed and their use in the production of preparations for use in the treatment of bacterial infections, particularly with drug resistant strains of bacteria of the genus 05-17-2012
20100093058High Transgene Expression Of A Pseudotyped Adeno-Associated Virus Type - The present invention related to methods and compositions comprising recombinant vectors comprising chimeric capsids and recombinant pseudotyped vectors with non-native capsid protein(s). The recombinant vectors of the invention confer an altered tropism that permits selective targeting of desired cells.04-15-2010
20120231525MULTIVALENT PHAGE DISPLAY SYSTEMS AND METHODS - The present invention relates to vectors, methods and systems for polypeptide display and selection. Specifically, the present invention relates to vectors, methods, and systems for multivalent phage display using pIX protein of filamentous phage and helper phage.09-13-2012
20120231524CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT - The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.09-13-2012
20120315686COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES - Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.12-13-2012
20120135501Recombinant poxvirus expressing homologous genes inserted - The present invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use of such recombinant poxvirus as medicament or vaccine. Additionally, a method for affecting preferably inducing, an immune response in a living animal, including a human, is provided.05-31-2012
20100173387METHOD FOR PRODUCING ADENOVIRUS VECTORS FOR GENE THERAPY AND DNA SEQUENCES USED THEREFOR - Method for producing adenovirus vectors for gene therapy and auxiliary vectors used therefor. The method is based on the multiplication of gutless adenoviruses that lack adenovirus-coding sequences by cotransfecting them with an auxiliary or helper adenovirus that has an attB sequence of the &phis;C31 bacteriophage inserted between the adenovirus packaging signal and the ITR closest to it and/or utilizing the delay arising at the time of packaging the helper adenovirus with respect to that of the gutless adenovirus owing to the presence of the atttB sequence in order to recover the gutless adenovirus from the culture before the helper adenovirus completes its viral cycle. This gives rise to high gutless adenovirus titres that are essentially free from helper adenovirus, thereby allowing them to be used in gene therapy, minimizing the likelihood of the appearance of a cellular immune response on the part of the treated individual against cells transduced by the adenovirus vector produced.07-08-2010
20100047895Methods for purification of bacterial cells and cell components - The present invention relates to a method for the selective purification of bacterial cells and/or cell components, whereby the purification is performed by means of a solid support.02-25-2010
20120178145VIRUS SCAFFOLD FOR SELF-ASSEMBLED, FLEXIBLE AND LIGHT LITHIUM BATTERY - A variety of compositions that include a metal oxide, films and batteries comprising one or more of the compositions, and methods of making the same.07-12-2012
20100273237Processes for Packaging Oligonucleotides Into Virus-Like Particles of RNA Bacteriophages - The invention provides processes for the producing compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle. The invention further provides processes for producing nucleotide compositions comprising oligonucleotides suitable to be used in the processes mentioned before. The invention further provides nucleotide compositions obtainable by the processes of the invention and uses thereof. The invention further provides compositions comprising (i) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage, and (ii) an oligonucleotide, wherein said oligonucleotide is packaged into said virus-like particle, wherein said compositions are obtainable by the processes of the invention and wherein said compositions preferably comprises a purity of at least 98%, most preferably of at least 99%.10-28-2010
20100009427Synthesis of fluorescent metal nanoclusters - Fluorescent metal nanoclusters were prepared.01-14-2010
20120225470METHODS OF PROPAGATING MONKEY ADENOVIRAL VECTORS - The invention provides methods for propagating a monkey adenovirus in a cell including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus. including a replication-deficient monkey adenovirus, obtained by such propagation methods.09-06-2012
20120329136METHODS AND COMPOSITIONS FOR THE PRODUCTION OF RECOMBINANT VIRUS VECTORS - A method for the production of a replication-deficient recombinant virus vector is disclosed. The replication-deficient recombinant virus vector has a recombinant virus genome with one or more defective viral genes. The method comprises infecting a host cell with a carrier virus having a carrier virus genome encoding one or more trans factors or variants thereof, incubating the infected host cell for a desired period of time, and isolating the replication-deficient recombinant virus vector. The carrier virus is a cytoplasmic virus that retains the carrier virus genome in the cytoplasm of the host cell. The host cell contains the recombinant viral genome and retains the recombinant viral genome in a nucleus of the host cell. Also disclosed is a carrier virus for the production of a replication-deficient recombinant virus vector.12-27-2012
20090017521Chimaeric phages - The invention relates to the field of generating helper phages and phage display libraries for the identification of binding molecules. The invention provide chimaeric phages having a coat comprising a protein mixture. The protein mixture comprises a fusion protein having a proteinaceous molecule fused to a functional form of a phage coat protein and a mutant form of the phage coat protein, wherein the mutant form is impaired in binding to a host cell receptor. The invention further provides new phage collections, novel helper phages and methods and means for producing chimaeric phages, infectious phages and helper phages.01-15-2009
20110124085UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION - Embodiments of the present invention provide methods and nucleic acid reporter molecules for the detection of nucleic acid in a sample. The nucleic acid reporter molecule comprises two unsymmetrical cyanine monomer moieties, which may be the same or different, that are covalently attached by a linker comprising at least one aromatic, heteroaromatic, cyclic or heterocyclic moiety comprising 3-20 non-hydrogen atoms selected from the group consisting of O, N, S, P and C. The linker may be rigid, relatively flexible or some degree thereof. The unsymmetrical cyanine monomer moieties comprise a substituted or unsubstituted benzazolium moiety and a substituted or unsubstituted pyridinium or quinolinium moiety that is connected by a methine bridge that is monomethine, trimethine or pentamethine. The linkers form the cyanine dimer compounds by attaching to the pyridinium or quinolinium moiety of the monomer moieties. The present nucleic acid reporter molecules find utility in forming a nucleic acid-reporter molecule complex and detecting the nucleic acid. In particular, present nucleic acid reporter molecules with a rigid linker and monomer moieties with a monomethine bridge find utility in detecting RNA in the presence of DNA.05-26-2011
20080299642VECTORS WITH MODIFIED PROTEASE-DEPENDENT TROPISM - The present invention provides cell fusogenic vectors having replicative ability, whose protease-dependent tropism has been modified. M gene-deficient viral vectors encoding modified F proteins, in which the cleavage site of the F protein of paramyxovirus is modified to be cleaved by different proteases, were produced. In cells transfected with these vectors, the genomic RNA present in the vectors is replicated, and cell fusogenic infection spreads to neighboring cells depending on the presence of other proteases; however, no viral particles are released. The vectors of this invention, encoding the F proteins which are cleaved by proteases whose activity is enhanced in cancer, show cancer growth suppressive effect in vivo.12-04-2008
20080299641Novel E. coli 0157:H7 bacteriophage and uses thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of 12-04-2008
20120264192ADENOVIRUS LIBRARY AND METHODS - Described herein is a method that generally includes infecting a host cell with a rescue adenovirus, wherein the rescue adenovirus genome comprises a loxP site and encodes at least one marker, and wherein the host cell comprises a library of polynucleotides that complement the adenovirus genome marker and encode a detectable polypeptide; incubating the infected host cell under conditions effective to permit recombination between the adenovirus genome and one or more of the library polynucleotides and the production of recombinant adenovirus particles comprising at least on detectable polypeptide; and detecting the at least one detectable polypeptide. Also described are adenovirus libraries constructed using such a method.10-18-2012
20080286848RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS - Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.11-20-2008
20090325269Bacteria/RNA extraction device - Apparatus and method for collection of a target material from a liquid sample comprising target species that contain the target material. The apparatus comprises a fluid flow conduit in communication with a filter medium having a pore size adapted to retain target species thereon and pass, as filtrate, lysate containing the desired target material. A lysing agent conduit communicates with the fluid flow conduit and delivers lysing agent to the filter medium to lyse the target cells thereby releasing the desired intracellular target material. The lysing agent may be recirculated through the filter medium for a sufficient time to permit sufficient quantity of lysate to circulate through the system for lysate collection and subsequent assay.12-31-2009
20120276612PHAGE OF ACINETOBACTER BAUMANNII - The present invention provides an isolated 11-01-2012
20120276613MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.11-01-2012
20130023030RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HYPIV2) FROM CDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS - Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.01-24-2013
20130023033PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM - The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript.01-24-2013
20130023031Pseudoinfectious Flavivirus and Uses Thereof - The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the 01-24-2013
20130023032Synergistic Attenuation of Vesicular Stomatitis Virus, Vectors Thereof and Immunogenic Compositions Thereof - The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV), More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.01-24-2013
20130171719RECOMBINANT AAV PRODUCTION IN MAMMALIAN CELLS - The present invention includes methods and compositions for the production of high titer recombinant Adeno-Associated Virus (rAAV) in a variety of mammalian cells. The disclosed rAAV are useful in gene therapy applications. Disclosed methods based on co-infection of cells with two or more replication-defective recombinant herpes virus (rHSV) vectors are suitable for high-titer, large-scale production of infectious rAAV.07-04-2013
20130095556NOVEL VESICULAR STOMATITIS VIRUS AND VIRUS RESCUE SYSTEM - The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.04-18-2013
20130102053Multi Plasmid System For The Production Of Influenza Virus - Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics.04-25-2013
20130130355METHOD AND SYSTEM OF PARTICLE-PHAGE EPITOPE COMPLEX - The present disclosure provides compositions and methods for using phage epitopes to profile the immune response. The phage epitopes can be used to detect one or more antibodies from a sample. Furthermore, the present disclosure provides methods and compositions for detecting a cancer based on the detection of one or more antibodies. In one embodiment, the antibody is an autoantibody. The present disclosure also provides methods of producing antibody detecting complexes.05-23-2013
20130143303Bionanomaterials and Their Synthesis - The use of biomaterials, such as viruses and virus-like particles, to form nanostructures is generally disclosed. For instance, rod-like viruses can be used to form composite nanofibers that are fixed together in a head-to-tail assembly by a polymer. Also, 2-dimensional nanostructures formed from crosslinked viruses assembled in a single, film-like layer are generally disclosed. Porous gels having controllable pore size through the use of virus particles are also disclosed.06-06-2013
20080206837Stable adenoviral vectors and methods for propagation thereof - Provided are methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B-55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.08-28-2008
20110217756NEWLY ISOLATED BACTERIOPHAGE SPECIFIC TO KLEBSIELLA PNEUMONIAE - A newly isolated lytic bacteriophage specifically against 09-08-2011
20080199939Adenoviral Vectors and Uses Thereof - The present invention relates to recombinant adenoviral vectors based on adenoviruses that encounter pre-existing immunity in a minority of the human population and which harbour a chimeric capsid. The chimeric capsid comprises fiber proteins that have at least the knob domain of a human adenovirus that binds to the Coxsackievirus and Adenovirus Receptor (CAR) and a hexon protein from an adenovirus serotype that encounters pre-existing immunity in a low percentage of the human population.08-21-2008
20110236957Nanoparticle Labeling Reagents and Methods of Use - Compositions and methods for labeling biological targets using a conjugate of a luminescent component and a targeting molecule attached to a nanoparticle core structure are described. The labeling conjugates offer high intensity and low background, and are ideal for histology and pathology.09-29-2011
20110275139RECOMBINANT VACCINIA VIRUS HAVING HEPATITIS C VIRUS GENE - Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above.11-10-2011
20100311145NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES - The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, whereby the gene is selected from the group comprising E1B55kDa, E4orf6, E4orf3 and E3ADP.12-09-2010
20130183740NOVEL METHOD FOR GENERATION OF RNA VIRUS - The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus which comprises at least one amino acid modification within the N-terminal cyto plasmic region of the NA protein.07-18-2013
20110294195EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 7a - Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.12-01-2011
20120003720NUCLEIC ACID DERIVED FROM HEPATITIS C VIRUS AND EXPRESSION VECTOR, TRANSFORMED CELL, AND HEPATITIS C VIRUS PARTICLES EACH PREPARED BY USING THE SAME - The present invention provides a nucleic acid comprises a 5′ untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3′ untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.01-05-2012
20120028336Single Recombination System and Methods of Use - The present invention is directed to a modified poxvirus vector that allows for the generation of recombinant poxviruses by a single recombination event. A modified poxvirus vector comprising at least one reporter gene located between two flanking sequences for homologous recombination is disclosed. Furthermore, a host cell comprising said vector and a method for the generation of recombinant poxviruses using said vector are provided.02-02-2012
20120028335ANTI-VIRAL AZIDE-CONTAINING COMPOUNDS - Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a human immunodeficiency virus with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.02-02-2012
20130196416PROTEIN AND NUCLEIC ACID DELIVERY VEHICLES, COMPONENTS AND MECHANISMS THEREOF - Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous, translocating DNA into finished phage heads as well as into proheads. Single motors can force exogenous DNA into phage heads at the same rate as into proheads and phage heads undergo repeated initiations, packaging multiple DNA molecules into the same head. This shows that the phage DNA packaging machine has unusual conformational plasticity, powering DNA into an apparently passive capsid receptacle, including the highly stable virus shell, until it is full. These features allow for the design of a novel class of nanocapsid delivery vehicles.08-01-2013
20130203151PRODUCTION OF ALPHAVIRUS REPLICON PARTICLES IN PACKAGING CELLS - Improvements in packaging cell systems for the high level production of recombinant virus replicon particles useful for directing expression of one or more heterologous gene products.08-08-2013
20120077248METHOD FOR DETERMINING CRYSTALLIZATION PARAMETERS AND APPARATUS FOR USE WITH THE SAME - The present disclosure provides a method to allow a user to pre-screen numerous crystallization conditions in the crystallization space to identify those conditions with the highest probability of yielding crystals and high quality diffracting crystals. In one embodiment, the dilute solution thermodynamic virial coefficient, termed B, is used to aid in the determination crystallization conditions that increase the probability of producing crystals for the crystallant of interest. The present disclosure also provide methods for predicting solution conditions that generate beneficial solubility and/or stability conditions for a polypeptide of interest using the B parameter. Devices for use in the described methods are also described.03-29-2012
20130095557IMMORTALIZED AVIAN CELL LINES - This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.04-18-2013

Patent applications in class VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING

Patent applications in all subclasses VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING